Estadístiques de Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
Visites totals
views | |
---|---|
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC) | 274 |
Visites totals per mes
views | |
---|---|
September 2024 | 4 |
October 2024 | 0 |
November 2024 | 0 |
December 2024 | 0 |
January 2025 | 0 |
February 2025 | 0 |
March 2025 | 0 |
Visites al fitxer
views | |
---|---|
mereu_anno_dual.pdf(legacy) | 239 |
mereu_anno_dual.pdf | 39 |
Vistes principals per país
views | |
---|---|
United States | 188 |
Spain | 25 |
Ireland | 15 |
Germany | 12 |
China | 5 |
Sweden | 5 |
France | 4 |
United Kingdom | 4 |
Japan | 3 |
Canada | 2 |
Mexico | 2 |
Slovenia | 2 |
Argentina | 1 |
Australia | 1 |
Czechia | 1 |
India | 1 |
Netherlands | 1 |
Turkey | 1 |
Ukraine | 1 |
Visites principals per ciutat
views | |
---|---|
Ashburn | 50 |
Fairfield | 39 |
Barcelona | 21 |
San Ramon | 17 |
Dublin | 15 |
Cambridge | 10 |
Ann Arbor | 9 |
Boardman | 8 |
Mountain View | 8 |
Menlo Park | 7 |
Seattle | 4 |
Shenzhen | 4 |
Jacksonville | 2 |
Mexico | 2 |
Redwood City | 2 |
San Diego | 2 |
Toronto | 2 |
Carcastillo | 1 |
Jerez | 1 |
Magdeburg | 1 |
Mumbai | 1 |
Philadelphia | 1 |
Rochester | 1 |
Ríudoms | 1 |
Shenyang | 1 |
Suipacha | 1 |
Telde | 1 |
Uppsala | 1 |